Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Nutlin-3||Nutlin|Nutlin-3a||MDM2 Inhibitor 20||Nutlin-3 is an MDM2 inhibitor which activates p53 and results in cancer cells undergoing apoptosis and cellular senescence. Nutlin-3 is a candidate for neoadjuvant therapy in cancers with a functional p53 (PMID: 18451145).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|RB1 inact mut||retinoblastoma||sensitive||Nutlin-3||Preclinical||Actionable||In a preclinical study, Nutlin-3a induced p53 pathway signaling in MDMX mouse models with retinoblastoma and 69% (70/102) of the eyes harvested from the mouse models demonstrated complete response or stable disease after 18 weeks of therapy (PMID: 21515735).||21515735|
|Unknown unknown||B-cell lymphoma||not applicable||Nutlin-3||Preclinical - Cell culture||Actionable||In a preclinical study, Nutlin-3 induced death of a mouse B-cell lymphoma cell line isolated from a tumor over expressing MYC in culture (PMID: 30069049).||30069049|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|